Treatment of adults w/ newly diagnosed chronic myeloid leukemia (CML) in chronic phase; chronic, accelerated or myeloid or lymphoid blast phase CML w/ resistance or intolerance to prior therapy including imatinib; Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) w/ resistance or intolerance to prior therapy including imatinib.